Overcoming antigen tolerance to develop GB22–45-2, an anti-DKK1 antibody for gastric cancer
In summary, these preclinical results suggest that GB22-45-2 is a potential therapeutic candidate for GC, laying the foundation for its future drug development.
Authors
- Wenjun Zhang
- Xiling Wei (ORCID: https://orcid.org/0000-0002-3777-9287)
- Yu Peng (ORCID: https://orcid.org/0000-0001-9116-1739)
- Wei Dong (ORCID: https://orcid.org/0000-0002-7632-2386)
- Tianqi Yin
- Suofu Qin (ORCID: https://orcid.org/0000-0002-3323-8846)
- Xiuli Guo
- Bo Liang (ORCID: https://orcid.org/0000-0001-6847-9968)
- Huiming Li
- Xiaodong Yang (ORCID: https://orcid.org/0000-0001-5630-5311)
- Ting Yao (ORCID: https://orcid.org/0000-0003-4605-6475)
Institutions
- Shandong University (CN)
- ZTE (China) (CN)
- Shandong Academy of Pharmaceutical Sciences (CN)
- China Development Bank (CN)
Publication Details
- Journal
- Antibody Therapeutics
- Published
- 2025-10-01
- DOI
- https://doi.org/10.1093/abt/tbaf024
- Primary Topic
- HER2/EGFR in Cancer Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00